Detailed information for compound 160610

Basic information

Technical information
  • TDR Targets ID: 160610
  • Name: 2-(phosphonomethylamino)acetic acid
  • MW: 169.073 | Formula: C3H8NO5P
  • H donors: 4 H acceptors: 5 LogP: -4.62 Rotable bonds: 4
    Rule of 5 violations (Lipinski): 1
  • SMILES: OC(=O)CNCP(=O)(O)O
  • InChi: 1S/C3H8NO5P/c5-3(6)1-4-2-10(7,8)9/h4H,1-2H2,(H,5,6)(H2,7,8,9)
  • InChiKey: XDDAORKBJWWYJS-UHFFFAOYSA-N  

Network

Hover on a compound node to display the structore

Synonyms

  • 2-(phosphonomethylamino)ethanoic acid
  • glyphosate
  • 40465-66-5
  • 1071-83-6
  • MON 2139
  • N-(Phosphonomethyl)glycine
  • NSC 151063
  • Spectrum3_000839
  • SpecPlus_000478
  • DivK1c_006574
  • NCGC00094536-01
  • NCGC00094536-02
  • KBio1_001518
  • N-(Phosphonomethyl) Glycine
  • Glyphosate, isopropylamine salt
  • N-Phosphonomethylglycine
  • ST5409039
  • WLN: QV1M1PQQO
  • AIDS-099067
  • AIDS099067
  • 79533_FLUKA
  • Spectrum4_000679
  • NCGC00014409
  • C01705
  • 337757_ALDRICH
  • NCI60_001060
  • ((phosphonomethyl)amino)acetic acid
  • NSC-151063
  • [(phosphonomethyl)amino]acetic acid
  • NCIStruc1_000002
  • 45521_RIEDEL
  • Spectrum5_001992
  • CHEBI:27744
  • KBioSS_002384
  • SPECTRUM330047
  • Spectrum2_001847
  • NCI151063
  • Anti-BOB
  • Anti-GPR15, N-Terminal antibody produced in rabbit
  • G4283_SIGMA
  • KBioGR_001117
  • Spectrum_001867
  • P9556_SIGMA
  • NCIStruc2_000104
  • KBio2_002380
  • KBio2_004948
  • KBio2_007516
  • SPBio_001634
  • Glyphosate, free acid
  • GPJ
  • BSPBio_002397
  • BRN 2045054
  • CCRIS 1587
  • CP 67573
  • Caswell No. 661A
  • EINECS 213-997-4
  • EPA Pesticide Chemical Code 417300
  • Glycine, N-(phosphonomethyl)-
  • Glyphosate - Trimesium Int.
  • Glyphosate [ANSI:BSI:ISO]
  • Glyphosate-trimesium Int.
  • Glyphosphate
  • HSDB 3432
  • KBio3_001897
  • MON 0573

Targets

Known targets for this compound

Species Target name Source Bibliographic reference
Thlaspi arvense Cytochrome P450 71B1 Starlite/ChEMBL References
Escherichia coli 5-enolpyruvylshikimate-3-phosphate synthetase Starlite/ChEMBL No references

Predicted pathogen targets for this compound

By orthology
Species Potential target Known druggable target/s Ortholog Group
Mycobacterium leprae probable 3-phosphoshikimate 1-carboxyvinyl transferase AroA (5-ENOLPYRUVYLSHIKIMATE-3-PHOSPHATE SYNTHASE) (EPSP SYNTHASE) (EPSPS Get druggable targets OG5_127183 All targets in OG5_127183
Mycobacterium leprae 3-dehydroquinate synthase AroB Get druggable targets OG5_127183 All targets in OG5_127183
Chlamydia trachomatis dehyroquinate synthase Get druggable targets OG5_127183 All targets in OG5_127183
Schistosoma mansoni 3-dehydroquinate synthase Get druggable targets OG5_127183 All targets in OG5_127183
Chlamydia trachomatis phosphoshikimate 1-carboxyl vinyltransferase Get druggable targets OG5_127183 All targets in OG5_127183
Candida albicans similar to S. cerevisiae ARO1 pentafunctional aromatic amino acid family biosynthesis protein Get druggable targets OG5_127183 All targets in OG5_127183
Mycobacterium tuberculosis 3-phosphoshikimate 1-carboxyvinyltransferase AroA (5-enolpyruvylshikimate-3-phosphate synthase) (EPSP synthase) (EPSPS) Get druggable targets OG5_127183 All targets in OG5_127183
Brugia malayi Cytochrome P450 family protein Get druggable targets OG5_126582 All targets in OG5_126582
Loa Loa (eye worm) cytochrome P450 family protein Get druggable targets OG5_126582 All targets in OG5_126582
Mycobacterium tuberculosis 3-dehydroquinate synthase AroB Get druggable targets OG5_127183 All targets in OG5_127183
Candida albicans similar to S. cerevisiae ARO1 pentafunctional aromatic amino acid family biosynthesis protein Get druggable targets OG5_127183 All targets in OG5_127183
Mycobacterium ulcerans 3-dehydroquinate synthase Get druggable targets OG5_127183 All targets in OG5_127183
Mycobacterium ulcerans 3-phosphoshikimate 1-carboxyvinyltransferase Get druggable targets OG5_127183 All targets in OG5_127183
Toxoplasma gondii shikimate dehydrogenase substrate binding domain-containing protein Get druggable targets OG5_127183 All targets in OG5_127183
Neospora caninum 3-dehydroquinate synthase (EC 4.2.3.4), related Get druggable targets OG5_127183 All targets in OG5_127183

By sequence similarity to non orthologous known druggable targets
Species Potential target Known druggable target Length Alignment span Identity
Brugia malayi cytochrome P450 Cytochrome P450 71B1   496 aa 481 aa 24.1 %
Onchocerca volvulus Cytochrome P450 71B1   496 aa 435 aa 24.8 %
Drosophila melanogaster Cytochrome P450-4d2 Cytochrome P450 71B1   496 aa 492 aa 22.1 %
Candida albicans cytochrome P450 similar to phenylacetate hydroxylase Cytochrome P450 71B1   496 aa 541 aa 20.3 %
Drosophila melanogaster shadow Cytochrome P450 71B1   496 aa 493 aa 22.1 %
Onchocerca volvulus Dynactin subunit 6 homolog Cytochrome P450 71B1   496 aa 490 aa 24.7 %
Candida albicans cytochrome P450 similar to phenylacetate hydroxylase Cytochrome P450 71B1   496 aa 541 aa 20.3 %
Drosophila melanogaster Cytochrome P450-4d1 Cytochrome P450 71B1   496 aa 487 aa 23.2 %
Echinococcus granulosus cytochrome P450 2K1 Cytochrome P450 71B1   496 aa 464 aa 20.5 %
Onchocerca volvulus Cytochrome P450 71B1   496 aa 503 aa 23.3 %
Drosophila melanogaster CG10242 gene product from transcript CG10242-RA Cytochrome P450 71B1   496 aa 492 aa 24.2 %
Drosophila melanogaster CG7241 gene product from transcript CG7241-RA Cytochrome P450 71B1   496 aa 514 aa 23.4 %
Brugia malayi Cytochrome P450 family protein Cytochrome P450 71B1   496 aa 463 aa 22.9 %
Loa Loa (eye worm) cytochrome P450 Cytochrome P450 71B1   496 aa 485 aa 24.3 %
Loa Loa (eye worm) cytochrome P450 family protein Cytochrome P450 71B1   496 aa 416 aa 21.2 %
Dictyostelium discoideum cytochrome P450 family protein Cytochrome P450 71B1   496 aa 451 aa 22.4 %

Obtained from network model

Ranking Plot


Putative Targets List


Species Potential target Raw Global Species
Loa Loa (eye worm) hypothetical protein 0.0164 0.0525 0.0525
Mycobacterium tuberculosis 3-phosphoshikimate 1-carboxyvinyltransferase AroA (5-enolpyruvylshikimate-3-phosphate synthase) (EPSP synthase) (EPSPS) 0.0139 0.0271 0.5
Echinococcus granulosus integrin alpha 3 0.0403 0.3009 0.4236
Schistosoma mansoni integrin alpha 0.0526 0.4282 0.4792
Loa Loa (eye worm) integrin beta-2 0.1076 1 1
Echinococcus multilocularis integrin alpha 3 0.0403 0.3009 0.4236
Brugia malayi Trypsin family protein 0.0974 0.8937 0.8878
Loa Loa (eye worm) integrin alpha pat-2 0.081 0.7236 0.7236
Schistosoma mansoni subfamily S1A unassigned peptidase (S01 family) 0.0974 0.8937 1
Mycobacterium tuberculosis 3-dehydroquinate synthase AroB 0.0139 0.0271 0.5
Loa Loa (eye worm) hypothetical protein 0.029 0.1837 0.1837
Loa Loa (eye worm) hypothetical protein 0.0123 0.0101 0.0101
Brugia malayi Integrin alpha pat-2 precursor 0.0526 0.4282 0.3965
Wolbachia endosymbiont of Brugia malayi UDP-N-acetylglucosamine 1-carboxyvinyltransferase 0.0218 0.1092 0.5
Echinococcus multilocularis integrin beta 2 0.0797 0.7104 1
Loa Loa (eye worm) hypothetical protein 0.0974 0.8937 0.8937
Schistosoma mansoni integrin beta subunit 0.0634 0.5407 0.605
Echinococcus granulosus integrin alpha ps 0.0236 0.1273 0.1792
Chlamydia trachomatis phosphoshikimate 1-carboxyl vinyltransferase 0.0357 0.2534 1
Chlamydia trachomatis UDP-N-acetylglucosamine 1-carboxyvinyltransferase 0.0218 0.1092 0.3627
Toxoplasma gondii shikimate dehydrogenase substrate binding domain-containing protein 0.0357 0.2534 0.5
Loa Loa (eye worm) hypothetical protein 0.0974 0.8937 0.8937
Loa Loa (eye worm) hypothetical protein 0.0413 0.311 0.311
Schistosoma mansoni subfamily S1A unassigned peptidase (S01 family) 0.0974 0.8937 1
Brugia malayi Integrin alpha cytoplasmic region family protein 0.0398 0.2954 0.2563
Treponema pallidum UDP-N-acetylglucosamine 1-carboxyvinyltransferase 0.0218 0.1092 0.5
Mycobacterium ulcerans 3-phosphoshikimate 1-carboxyvinyltransferase 0.0357 0.2534 1
Onchocerca volvulus 0.0974 0.8937 1
Loa Loa (eye worm) kelch domain-containing protein family protein 0.0164 0.0525 0.0525
Schistosoma mansoni integrin alpha-ps 0.0236 0.1273 0.1425
Echinococcus multilocularis integrin alpha ps 0.0236 0.1273 0.1792
Mycobacterium leprae probable 3-phosphoshikimate 1-carboxyvinyl transferase AroA (5-ENOLPYRUVYLSHIKIMATE-3-PHOSPHATE SYNTHASE) (EPSP SYNTHASE) (EPSPS 0.0357 0.2534 1
Echinococcus multilocularis integrin alpha ps 0.0236 0.1273 0.1792
Schistosoma mansoni 3-dehydroquinate synthase 0.0139 0.0271 0.0303
Mycobacterium ulcerans UDP-N-acetylglucosamine 1-carboxyvinyltransferase 0.0218 0.1092 0.3627
Echinococcus granulosus integrin beta 2 0.0797 0.7104 1
Loa Loa (eye worm) hypothetical protein 0.0398 0.2954 0.2954
Schistosoma mansoni integrin alpha-ps 0.0123 0.0101 0.0113

Activities

Activity type Activity value Assay description Source Reference
AC50 (functional) PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp3a4 Compounds with AC50 equal or less than 10 uM are considered active ChEMBL. No reference
AC50 (functional) PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2c19 Compounds with AC50 equal or less than 10 uM are considered active ChEMBL. No reference
AC50 (functional) PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp1a2 Compounds with AC50 equal or less than 10 uM are considered active ChEMBL. No reference
AC50 (functional) PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2c9 Compounds with AC50 equal or less than 10 uM are considered active ChEMBL. No reference
AC50 (functional) PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2d6 Compounds with AC50 equal or less than 10 uM are considered active ChEMBL. No reference
GI (functional) Herbicidal activity against Arabidopsis thaliana assessed as growth inhibition at 10 ppm by 96-well plate test ChEMBL. 21970768
GI50 (functional) -4 PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SN12C Renal cell line. (Class of assay: confirmatory) ChEMBL. No reference
GI50 (functional) -4 PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the MDA-N Breast cell line. (Class of assay: confirmatory) ChEMBL. No reference
GI50 (functional) -4 PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the NCI-H23 Non-Small Cell Lung cell line. (Class of assay: confirmatory) ChEMBL. No reference
GI50 (functional) -4 PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the ACHN Renal cell line. (Class of assay: confirmatory) ChEMBL. No reference
GI50 (functional) -4 PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the HOP-92 Non-Small Cell Lung cell line. (Class of assay: confirmatory) ChEMBL. No reference
GI50 (functional) -4 PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the HL-60(TB) Leukemia cell line. (Class of assay: confirmatory) ChEMBL. No reference
GI50 (functional) -4 PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the DU-145 Prostate cell line. (Class of assay: confirmatory) ChEMBL. No reference
GI50 (functional) -4 PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SF-539 Central Nervous System cell line. (Class of assay: confirmatory) ChEMBL. No reference
GI50 (functional) -4 PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the MALME-3M Melanoma cell line. (Class of assay: confirmatory) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: Protein Tyrosine Kinase, LCK enzyme inhibition (substrate: Poly(Glu:Tyr)) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: Angiotensin AT2 radioligand binding (ligand: [125I] CGP-42112A) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: Cholecystokinin CCKA radioligand binding (ligand: [3H] L-364,718) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: Protein Serine/Threonine Kinase, ERK2 enzyme inhibition (substrate: Myelin Basic Protein) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: Melanocortin MC4 radioligand binding (ligand: [125I] NDP-alpha-MSH) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: Protease, Cathepsin G enzyme inhibition (substrate: Suc-Ala-Ala-Pro-Phe-AMC) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: Peptidase, Angiotensin Converting Enzyme enzyme inhibition (substrate: FAPGG) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: Protein Serine/Threonine Phosphatase, PPP3CA (Calcineurin, PP2B) enzyme inhibition (substrate: DiFMUP) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: Calcitonin radioligand binding (ligand: [125I] Calcitonin (salmon)) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: Chemokine CCR2B radioligand binding (ligand: [125I] MCP-1) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: Insulin radioligand binding (ligand: [125I] Insulin) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: Cannabinoid CB1 radioligand binding (ligand: [3H] SR141716A) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: Endothelin ETA radioligand binding (ligand: [125I] Endothelin-1) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: Chemokine CCR4 radioligand binding (ligand: [125I] TARC) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: Bradykinin B2 radioligand binding (ligand: [3H] Bradykinin) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: CYP450, 2E1 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: Acetylcholinesterase enzyme inhibition (substrate: acetylthiocholine) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: Adrenergic beta1 radioligand binding (ligand: [125I] Cyanopindolol) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: Protein Serine/Threonine Kinase PKCalpha enzyme inhibition (substrate: Histone) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: Protease, Caspase 1 enzyme inhibition (substrate: Ac-YVAD-AMC) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: Chemokine CXCR1 (IL-8A) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: Vasopressin V1A radioligand binding (ligand: [125I] PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: Carbonic Anhydrase II enzyme inhibition (substrate: 4-Nitrophenyl acetate (4-NPA)) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: Nitric Oxide Synthase, Neuronal (nNOS) radioligand binding (ligand: [3H]L-Arginine) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: Chemokine CCR5 radioligand binding (ligand: [125I] MIP-1alpha) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: Vasoactive Intestinal Peptide VIP1 radioligand binding (ligand: [125I] VIP) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: Melanocortin MC5 radioligand binding (ligand: [125I] NDP-alpha-MSH) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr)) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: Peptidase, ELA2 (Neutrophil Elastase 2) enzyme inhibition (substrate: N-MeOSuc-Ala-Ala-Pro-Val-pNA) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: CYP450, 2A6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: Neuropeptide Y Y1 radioligand binding (ligand: [125I] Peptide YY) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: Tachykinin NK1 radioligand binding (ligand: [3H] Substance P) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: Platelet Activating Factor (PAF) radioligand binding (ligand: [3H] PAF) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: HMG-CoA Reductase enzyme inhibition (substrate: [14C]HMG-CoA) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: Melanocortin MC3 radioligand binding (ligand: [125I] NDP-alpha-MSH) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: Protein Serine/Threonine Kinase, p38alpha enzyme inhibition (substrate: Myelin Basic Protein) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: Peptidase, Matrix Metalloprotease-1 (MMP-1) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: Neuropeptide Y Y2 radioligand binding (ligand: [125I] Peptide YY) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: Phosphodiesterase PDE5 enzyme inhibition (substrate: [3H]cGMP + cGMP) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55) ChEMBL. No reference
IC50 (binding) DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390) ChEMBL. No reference
IC50 (binding) = 2 uM Tested for the inhibition against E. coli 5-enolpyruvyl-shikimate-3-phosphate synthase ChEMBL. No reference
IC50 (binding) = 2 uM Tested for the inhibition against E. coli 5-enolpyruvyl-shikimate-3-phosphate synthase ChEMBL. No reference
IC50 (binding) = 12 uM Inhibition of Thlaspi arvense CPR-fused CYP71B1 expressed in Escherichia coli DH5alpha assessed as conversion of benzo(a)pyrene to 3-hydroxybenzo(a)pyrene ChEMBL. 9514851
IC50 (binding) = 100 uM Inhibition of glutamine synthetase in Nicotiana tabacum (tobacco) cells ChEMBL. 17474756
IC50 (binding) = 100 uM Inhibition of Spinacia oleracea (spinach) glutamine synthetase activity ChEMBL. 17474756
Inhibition (ADMET) = 99.87449448 % Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM ChEMBL. 23571415
Inhibition (ADMET) = 130.3183724 % Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM ChEMBL. 23571415
Kd (binding) = 0.16 uM Tested for the dissociation constant against E. coli 5-enolpyruvyl-shikimate-3-phosphate synthase ChEMBL. No reference
Kd (binding) = 0.16 uM Tested for the dissociation constant against E. coli 5-enolpyruvyl-shikimate-3-phosphate synthase ChEMBL. No reference
Ki (binding) DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine) ChEMBL. No reference
Ki (binding) DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol) ChEMBL. No reference
Ki (binding) DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55) ChEMBL. No reference
Ki (binding) DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine) ChEMBL. No reference
Ki (binding) DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide) ChEMBL. No reference
Ki (binding) DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177) ChEMBL. No reference
Ki (binding) DRUGMATRIX: Melanocortin MC3 radioligand binding (ligand: [125I] NDP-alpha-MSH) ChEMBL. No reference
Ki (binding) DRUGMATRIX: Protease, Cathepsin G enzyme inhibition (substrate: Suc-Ala-Ala-Pro-Phe-AMC) ChEMBL. No reference
Ki (binding) DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin) ChEMBL. No reference
Ki (binding) DRUGMATRIX: Protein Tyrosine Kinase, LCK enzyme inhibition (substrate: Poly(Glu:Tyr)) ChEMBL. No reference
Ki (binding) DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid) ChEMBL. No reference
Ki (binding) DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin) ChEMBL. No reference
Ki (binding) DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912) ChEMBL. No reference
Ki (binding) DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX) ChEMBL. No reference
Ki (binding) DRUGMATRIX: Neuropeptide Y Y2 radioligand binding (ligand: [125I] Peptide YY) ChEMBL. No reference
Ki (binding) DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine) ChEMBL. No reference
Ki (binding) DRUGMATRIX: Carbonic Anhydrase II enzyme inhibition (substrate: 4-Nitrophenyl acetate (4-NPA)) ChEMBL. No reference
Ki (binding) DRUGMATRIX: CYP450, 2E1 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin) ChEMBL. No reference
Ki (binding) DRUGMATRIX: Angiotensin AT2 radioligand binding (ligand: [125I] CGP-42112A) ChEMBL. No reference
Ki (binding) DRUGMATRIX: Melanocortin MC5 radioligand binding (ligand: [125I] NDP-alpha-MSH) ChEMBL. No reference
Ki (binding) DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA) ChEMBL. No reference
Ki (binding) DRUGMATRIX: Chemokine CCR4 radioligand binding (ligand: [125I] TARC) ChEMBL. No reference
Ki (binding) DRUGMATRIX: Nitric Oxide Synthase, Neuronal (nNOS) radioligand binding (ligand: [3H]L-Arginine) ChEMBL. No reference
Ki (binding) DRUGMATRIX: Protein Serine/Threonine Kinase, p38alpha enzyme inhibition (substrate: Myelin Basic Protein) ChEMBL. No reference
Ki (binding) DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine) ChEMBL. No reference
Ki (binding) DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid) ChEMBL. No reference
Ki (binding) DRUGMATRIX: Protein Serine/Threonine Kinase, ERK2 enzyme inhibition (substrate: Myelin Basic Protein) ChEMBL. No reference
Ki (binding) DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin) ChEMBL. No reference
Ki (binding) DRUGMATRIX: Cannabinoid CB1 radioligand binding (ligand: [3H] SR141716A) ChEMBL. No reference
Ki (binding) DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968) ChEMBL. No reference
Ki (binding) DRUGMATRIX: Cholecystokinin CCKA radioligand binding (ligand: [3H] L-364,718) ChEMBL. No reference
Ki (binding) DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide) ChEMBL. No reference
Ki (binding) DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde) ChEMBL. No reference
Ki (binding) DRUGMATRIX: Chemokine CCR5 radioligand binding (ligand: [125I] MIP-1alpha) ChEMBL. No reference
Ki (binding) DRUGMATRIX: Chemokine CXCR1 (IL-8A) ChEMBL. No reference
Ki (binding) DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4) ChEMBL. No reference
Ki (binding) DRUGMATRIX: CYP450, 2A6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin) ChEMBL. No reference
Ki (binding) DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid) ChEMBL. No reference
Ki (binding) DRUGMATRIX: Tachykinin NK1 radioligand binding (ligand: [3H] Substance P) ChEMBL. No reference
Ki (binding) DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine) ChEMBL. No reference
Ki (binding) DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr)) ChEMBL. No reference
Ki (binding) DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine) ChEMBL. No reference
Ki (binding) DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein) ChEMBL. No reference
Ki (binding) DRUGMATRIX: Protease, Caspase 1 enzyme inhibition (substrate: Ac-YVAD-AMC) ChEMBL. No reference
Ki (binding) DRUGMATRIX: Chemokine CCR2B radioligand binding (ligand: [125I] MCP-1) ChEMBL. No reference
Ki (binding) DRUGMATRIX: Peptidase, ELA2 (Neutrophil Elastase 2) enzyme inhibition (substrate: N-MeOSuc-Ala-Ala-Pro-Val-pNA) ChEMBL. No reference
Ki (binding) DRUGMATRIX: Peptidase, Angiotensin Converting Enzyme enzyme inhibition (substrate: FAPGG) ChEMBL. No reference
Ki (binding) DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine) ChEMBL. No reference
Ki (binding) DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin) ChEMBL. No reference
Ki (binding) DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine) ChEMBL. No reference
Ki (binding) DRUGMATRIX: Calcitonin radioligand binding (ligand: [125I] Calcitonin (salmon)) ChEMBL. No reference
Ki (binding) DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine) ChEMBL. No reference
Ki (binding) DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT) ChEMBL. No reference
Ki (binding) DRUGMATRIX: Peptidase, Matrix Metalloprotease-1 (MMP-1) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2) ChEMBL. No reference
Ki (binding) DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone) ChEMBL. No reference
Ki (binding) DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4) ChEMBL. No reference
Ki (binding) DRUGMATRIX: Acetylcholinesterase enzyme inhibition (substrate: acetylthiocholine) ChEMBL. No reference
Ki (binding) DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol) ChEMBL. No reference
Ki (binding) DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912) ChEMBL. No reference
Ki (binding) DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020) ChEMBL. No reference
Ki (binding) DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin) ChEMBL. No reference
Ki (binding) DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin) ChEMBL. No reference
Ki (binding) DRUGMATRIX: Phosphodiesterase PDE5 enzyme inhibition (substrate: [3H]cGMP + cGMP) ChEMBL. No reference
Ki (binding) DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin) ChEMBL. No reference
Ki (binding) DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2) ChEMBL. No reference
Ki (binding) DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol) ChEMBL. No reference
Ki (binding) DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine) ChEMBL. No reference
Ki (binding) DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8) ChEMBL. No reference
Ki (binding) DRUGMATRIX: Protein Serine/Threonine Phosphatase, PPP3CA (Calcineurin, PP2B) enzyme inhibition (substrate: DiFMUP) ChEMBL. No reference
Ki (binding) DRUGMATRIX: Vasopressin V1A radioligand binding (ligand: [125I] PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr) ChEMBL. No reference
Ki (binding) DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone) ChEMBL. No reference
Ki (binding) DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA) ChEMBL. No reference
Ki (binding) DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2) ChEMBL. No reference
Ki (binding) DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin) ChEMBL. No reference
Ki (binding) DRUGMATRIX: Endothelin ETA radioligand binding (ligand: [125I] Endothelin-1) ChEMBL. No reference
Ki (binding) DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole) ChEMBL. No reference
Ki (binding) DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone) ChEMBL. No reference
Ki (binding) DRUGMATRIX: HMG-CoA Reductase enzyme inhibition (substrate: [14C]HMG-CoA) ChEMBL. No reference
Ki (binding) DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol) ChEMBL. No reference
Ki (binding) DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine) ChEMBL. No reference
Ki (binding) DRUGMATRIX: Insulin radioligand binding (ligand: [125I] Insulin) ChEMBL. No reference
Ki (binding) DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808) ChEMBL. No reference
Ki (binding) DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone) ChEMBL. No reference
Ki (binding) DRUGMATRIX: Melanocortin MC4 radioligand binding (ligand: [125I] NDP-alpha-MSH) ChEMBL. No reference
Ki (binding) DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390) ChEMBL. No reference
Ki (binding) DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine) ChEMBL. No reference
Ki (binding) DRUGMATRIX: Platelet Activating Factor (PAF) radioligand binding (ligand: [3H] PAF) ChEMBL. No reference
Ki (binding) DRUGMATRIX: Neuropeptide Y Y1 radioligand binding (ligand: [125I] Peptide YY) ChEMBL. No reference
Ki (binding) DRUGMATRIX: Protein Serine/Threonine Kinase PKCalpha enzyme inhibition (substrate: Histone) ChEMBL. No reference
Ki (binding) DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55) ChEMBL. No reference
Ki (binding) DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine) ChEMBL. No reference
Ki (binding) DRUGMATRIX: Vasoactive Intestinal Peptide VIP1 radioligand binding (ligand: [125I] VIP) ChEMBL. No reference
Ki (binding) DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol) ChEMBL. No reference
Ki (binding) DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine) ChEMBL. No reference
Ki (binding) DRUGMATRIX: Bradykinin B2 radioligand binding (ligand: [3H] Bradykinin) ChEMBL. No reference
Ki (binding) DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin) ChEMBL. No reference
Ki (binding) = 0.16 uM Tested for the inhibition against E. coli 5-enolpyruvyl-shikimate-3-phosphate synthase versus phosphoenolpyruvate ChEMBL. No reference
Ki (binding) = 0.16 uM Tested for the inhibition against E. coli 5-enolpyruvyl-shikimate-3-phosphate synthase versus phosphoenolpyruvate ChEMBL. No reference
Ki (binding) = 260 uM Competitive inhibition of Neisseria meningitidis serotype B strain MC58 ATCC BAA355 KDO8P synthase expressed in Escherichia coli BL21 (DE3) cells using PEP as substrate after 10 to 15 mins by Michaelis-Menten equation ChEMBL. 22204912
Koff (binding) = 0.12 s-1 Tested for the dissociation rate against E. coli 5-enolpyruvyl-shikimate-3-phosphate synthase ChEMBL. No reference
Kon (binding) = 0.78 uM-1 s-1 Tested for the rate of association against E. coli 5-enolpyruvyl-shikimate-3-phosphate synthase ChEMBL. No reference
Ks (binding) = 60 uM Binding affinity to Thlaspi arvense CPR-fused CYP71B1 expressed in Escherichia coli DH5alpha ChEMBL. 9514851
k_off (binding) = 0.12 s-1 Tested for the dissociation rate against E. coli 5-enolpyruvyl-shikimate-3-phosphate synthase ChEMBL. No reference
k_on (binding) = 0.7799999999999999 uM-1 s-1 Tested for the rate of association against E. coli 5-enolpyruvyl-shikimate-3-phosphate synthase ChEMBL. No reference
k_on (binding) = 0.78 uM-1 s-1 Tested for the rate of association against E. coli 5-enolpyruvyl-shikimate-3-phosphate synthase ChEMBL. No reference

Phenotypes

Whole-cell/tissue/organism interactions

We have no records of whole-cell/tissue assays done with this compound What does this mean?

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

Bibliographic References

5 literature references were collected for this gene.

If you have references for this compound, please enter them in a user comment (below) or Contact us.